Coya Therapeutics, Ownership
| COYA Stock | 6.04 0.31 4.88% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Coya |
Coya Stock Ownership Analysis
About 20.0% of the company shares are held by institutions such as insurance companies. The book value of Coya Therapeutics, was currently reported as 2.1. The company recorded a loss per share of 0.65. Coya Therapeutics, Common had not issued any dividends in recent years. For more info on Coya Therapeutics, Common please contact the company at 800 587 8170 or go to https://www.coyatherapeutics.com.Besides selling stocks to institutional investors, Coya Therapeutics, also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Coya Therapeutics,'s stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Coya Therapeutics,'s strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Coya Therapeutics, Quarterly Liabilities And Stockholders Equity |
|
Coya Therapeutics, Insider Trades History
About 7.0% of Coya Therapeutics, Common are currently held by insiders. Unlike Coya Therapeutics,'s institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Coya Therapeutics,'s private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Coya Therapeutics,'s insider trades
Coya Therapeutics, Common Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Coya Therapeutics, insiders, such as employees or executives, is commonly permitted as long as it does not rely on Coya Therapeutics,'s material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Coya Therapeutics, insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Coya Therapeutics, Corporate Filings
| 29th of November 2024 Other Reports | ViewVerify | |
| 20th of November 2024 Other Reports | ViewVerify | |
F4 | 14th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 12th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Coya Therapeutics, Common offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Coya Therapeutics,'s financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Coya Therapeutics, Common Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Coya Therapeutics, Common Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Coya Therapeutics, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Coya Therapeutics,. If investors know Coya will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Coya Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.65) | Revenue Per Share 0.687 | Return On Assets (0.29) | Return On Equity (0.51) |
The market value of Coya Therapeutics, Common is measured differently than its book value, which is the value of Coya that is recorded on the company's balance sheet. Investors also form their own opinion of Coya Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Coya Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Coya Therapeutics,'s market value can be influenced by many factors that don't directly affect Coya Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Coya Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Coya Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Coya Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.